{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:37:58Z","timestamp":1783705078368,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Limited information is available on patients with systemic juvenile idiopathic arthritis (sJIA) receiving biologics in Japan. The types of biologics, treatment duration, prior and concomitant treatments, administration route (intravenous [IV] or subcutaneous [SC] injection), treatment sequence, and characteristics of patients receiving biologics were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from a Japanese hospital claims database (2008\u201324).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 2000 sJIA patients in the database, 315 (15.8%) received one or more biologics. For the first biologic, the most common were anti-interleukin-6 (anti-IL-6) drugs (82.5%; tocilizumab, 82.2% [IV, 65.1%; SC, 17.1%]; others, &amp;lt;0.4%), followed by anti-tumour necrosis factor drugs (11.7%; adalimumab SC, 4.4%; infliximab IV, 4.1%; others, &amp;lt;\u20091.6% each), canakinumab SC (3.8%), and abatacept IV or SC (1.9%). Over 53% of patients received anti-IL-6 drugs for \u22651\u00a0year. The most common conventional synthetic disease-modifying antirheumatic drugs administered prior to anti-IL-6 drugs were cyclosporine (11.9%), methotrexate (11.5%), and tacrolimus (6.2%), and those most commonly administered concomitantly with anti-IL-6 drugs were methotrexate (22.7%), cyclosporine (16.9%), and tacrolimus (11.5%). Fifty patients switched from tocilizumab IV to a second biologic (tocilizumab SC, 50.0%; canakinumab SC, 36.0%; others \u22644.0% each).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study described the real-world usage of biologics for sJIA in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf083","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:53:02Z","timestamp":1757677982000},"page":"113-121","source":"Crossref","is-referenced-by-count":1,"title":["Real-world use of biologics for systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database"],"prefix":"10.1093","volume":"36","author":[{"given":"Takashi","family":"Funatogawa","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mii","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Aoki","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hoshiba","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. \u00a0 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"2025122205122134600_ref1","first-page":"390","article-title":"International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2025122205122134600_ref2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14397595.2018.1514724","article-title":"Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018","volume":"29","author":"Okamoto","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025122205122134600_ref3","author":"Japan Intractable Diseases Information Center (in Japanese)"},{"key":"2025122205122134600_ref4","volume-title":"Guide to the Use of Biologics in Juvenile Idiopathic Arthritis (JIA)","author":"Pediatric Rheumatology Association of Japan, Japan College of Rheumatology","year":"2020"},{"key":"2025122205122134600_ref5","author":"Japan College of Rheumatology. Guide to support patients with juvenile idiopathic arthritis Part I: for medical staff (in Japanese)","year":"2023"},{"key":"2025122205122134600_ref6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2025122205122134600_ref7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2025122205122134600_ref8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2025122205122134600_ref9","author":"Medical Data Vision Co., Ltd"},{"key":"2025122205122134600_ref10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025122205122134600_ref11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025122205122134600_ref12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025122205122134600_ref13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41584-022-00787-3","article-title":"2021 ACR guideline for JIA reflects changes in practice","volume":"18","author":"Naddei","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025122205122134600_ref14","first-page":"e217","article-title":"BCRD and BSPAR-ETN study groups. Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. Lancet","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf083\/64261527\/roaf083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/113\/64261527\/roaf083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/113\/64261527\/roaf083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:12:45Z","timestamp":1766398365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/1\/113\/8253502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,13]]},"published-print":{"date-parts":[[2025,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf083","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,13]]}}}